Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: July 2010
-
By Juan Serrano — The Mexican General Health Law was reformed on June 11, 2009 to include an article 222 bis, which defined biotechnological drugs, and allowed for the approval of "biocomparables." The decree came into force on September 8, 2009, and the Ministry of Health had a 180-day period to issue all specific…
-
By Donald Zuhn — Last week, the U.S. Patent and Trademark Office published a notice in the Federal Register (75 Fed. Reg. 42079) to clarify how the Office will treat certain letters submitted by applicants and patentees regarding the Office's patent term adjustment (PTA) determinations. In particular, the notice addresses situations in which an…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Roche Palo Alto LLC et al. v. Lupin Pharmaceuticals, Inc. et al.1:10-cv-01988; filed July 20, 2010 in the District Court of Maryland • Plaintiffs: Roche Palo Alto LLC; Gilead Palo Alto, Inc.; Gilead Sciences,…
-
July 26-27, 2010 – Advanced Patent Prosecution Workshop 2010: Claim Drafting & Amendment Writing (Practising Law Institute) – New York, NY July 29-31, 2010 – Intensive Patent Law Training Workshop (Chisum Patent Academy) – Seattle, WA August 5-10, 2010 – 2010 ABA Annual Meeting (American Bar Association) – San Francisco, CA August 11, 2010 –…
-
American Conference Institute (ACI) will be holding its 11th Maximizing Pharmaceutical Patent Lifecycles conference on October 6-7, 2010 in New York, NY. The conference will allow attendees to: • Understand how the introduction of biosimilars has profoundly altered pharmaceutical patent life cycle strategies;• Appreciate the relationship between life cycle management, brand optimization and new product…
-
American Conference Institute (ACI) will be holding the next session of its FDA Boot Camp conference on September 27-28, 2010 in Boston, MA. ACI faculty will help attendees: • Master the complexities of pharmaceutical iP and the regulatory balance between brand name and generic products;• Analyze the future of follow-on biologics following recent health care…
-
By James DeGiulio — Teva and Novartis Settle Patent Dispute over Zometa Teva Pharmaceuticals Industries Ltd. and Novartis Corp. have reached an agreement to settle their patent suit over a generic version of Zometa, a drug used to prevent skeletal fractures. Teva first sent Novartis two Paragraph IV notices on June 10, 2008, claiming…
-
By Donald Zuhn — Last week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the second quarter of 2010. The NVCA quarterly study, which the NVCA conducts with PriceWaterhouseCoopers using data from Thomson Reuters, indicates that…
-
By Sarah Fendrick — The U.S. Patent and Trademark Office recently published a notice in the Federal Register (75 Fed. Reg. 29321) announcing that the Office will streamline procedures for the review of appeal briefs in ex parte reexamination proceeding appeals. The new procedures were implemented in an effort to increase the efficiency of…
-
By Donald Zuhn — In a notice published in the Federal Register earlier this month (75 Fed. Reg. 39493), the U.S. Patent and Trademark Office announced that its draft strategic plan for FY 2010–2015 has been made available for public review and comment. The Office notes that the plan is a revision of the…
Patent Docs 